BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38716597)

  • 21. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
    Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
    Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
    Huang Z; Jia Y; Ruan G; Zuo Y; Wu J; Lu A; Xue Y; Cheng Y; Zhang L
    Pediatr Hematol Oncol; 2022 Apr; 39(3):243-253. PubMed ID: 34582325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia.
    Wang ZD; Wang YW; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Wang YZ; Liu YR; Liu KY; Huang XJ; Chang YJ
    Curr Med Sci; 2021 Jun; 41(3):443-453. PubMed ID: 34185250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
    Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
    Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
    Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
    Ribera J; Zamora L; Morgades M; Vives S; Granada I; Montesinos P; Gómez-Seguí I; Mercadal S; Guàrdia R; Nomdedeu J; Pratcorona M; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; Ciudad J; Orfao A; González-Campos J; Barba P; Escoda L; Esteve J; Genescà E; Solé F; Feliu E; Ribera JM; ;
    Genes Chromosomes Cancer; 2019 Nov; 58(11):815-819. PubMed ID: 31340073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of IKZF1
    Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss-of-function but not dominant-negative intragenic
    Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
    Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
    Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
    Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
    Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Srinivasan S; Ramanathan S; Kumar S; Peyam S; Radhakrishnan V
    Ann Hematol; 2023 Aug; 102(8):2165-2179. PubMed ID: 37154889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The prognostic significance of minimal residual disease detection after first induction treatment in adult acute lymphoblastic leukemia patients treated with autologous stem cell transplantation].
    Huang ZF; Xu J; Fu MW; Wang TY; Hao M; Liu W; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):105-110. PubMed ID: 30831624
    [No Abstract]   [Full Text] [Related]  

  • 38. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
    Yeoh AEJ; Lu Y; Chin WHN; Chiew EKH; Lim EH; Li Z; Kham SKY; Chan YH; Abdullah WA; Lin HP; Chan LL; Lam JCM; Tan PL; Quah TC; Tan AM; Ariffin H
    J Clin Oncol; 2018 Sep; 36(26):2726-2735. PubMed ID: 30044693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
    Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
    van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
    Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.